Impact and operational feasibility of adding malaria infection screening using an ultrasensitive RDT for placental and fetal outcomes in an area of high IPTP-SP coverage in Burkina Faso: the ASSER MALARIA pilot study protocol

Marc Christian Tahita, Paul Sondo, Berenger Kabore, Hamidou Ilboudo, Toussaint Rouamba, Hyacinthe Sanou, Kadija Ouédraogo, Adélaïde Compaoré, Palpouguini Lompo, Florence Ouedraogo, Seydou Sawadogo, Karim Derra, Yabré Edmond Sawadogo, Athanase M Somé, Macaire Nana, Hermann Sorgho, Maminata Traore-Coulibaly, Quique Bassat, Halidou Tinto, Marc Christian Tahita, Paul Sondo, Berenger Kabore, Hamidou Ilboudo, Toussaint Rouamba, Hyacinthe Sanou, Kadija Ouédraogo, Adélaïde Compaoré, Palpouguini Lompo, Florence Ouedraogo, Seydou Sawadogo, Karim Derra, Yabré Edmond Sawadogo, Athanase M Somé, Macaire Nana, Hermann Sorgho, Maminata Traore-Coulibaly, Quique Bassat, Halidou Tinto

Abstract

Background: Malaria infection during pregnancy (MIP) is not only deleterious to the woman, but it also puts her fetus at increased risk of adverse outcomes, such as preterm delivery, low birth weight, and intrauterine growth retardation. Additionally, all-cause mortality during the first year of life in babies born to women with malaria during pregnancy is also increased. Many interventions such as IPTp-SP and long-lasting insecticidal nets have proven to be efficient at reducing malaria in pregnancy burden but adherence to recommended policies remains poor. In sub-Saharan Africa, malaria in pregnancy is often asymptomatic and many malaria infections may be missed due to the inadequate performance of the current rapid diagnostic test to detect low-level parasitemias. Therefore, additional strategies such as intermittent screening with ultrasensitive rapid diagnostic tests and treatment with an effective artemisinin-based combination therapy in addition to IPTp-SP could reduce placental malaria, peripheral malaria infection at delivery, and low birth weight.

Methods: This pilot 2-group randomized open trial with a nested qualitative social behavioral will be carried out in Nanoro district in which 340 pregnant women will be recruited. Pregnant women will be randomized into two groups and followed on a monthly basis until delivery. In the intervention group, monthly screening using ultrasensitive rapid diagnostic tests and treatment of those found to be infected with dihydroartemisinin-piperaquine will be performed. In addition, a reminder will be sent to increase the uptake of IPTp-SP doses per woman. During scheduled and unscheduled visits, malaria infection, hemoglobin level, and other clinical outcomes will be assessed and compared by the group. The primary feasibility outcome will evaluate the study site's capacity to enroll participants and the women's perception and acceptability of the intervention. The primary clinical outcome will be the prevalence of placental malaria at delivery.

Discussion: The present protocol aims to evaluate the feasibility on a large-scale and also to demonstrate the impact and the operational feasibility of additional screening with ultrasensitive rapid diagnostic tests and treatment with DHA-PQ on placental malaria, low birth weight, and peripheral malaria infection at delivery in a high-burden setting in Burkina Faso.

Trial registration: ClinicalTrials.gov , ID: NCT04147546 (14 October 2019).

Keywords: IPTp; Intermittent screening and treatment; Malaria in pregnancy; Placental malaria; Ultrasensitive RDTs.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Schematic of study design

References

    1. Walker PGT, ter Kuile FO, Garske T, Menendez C, Ghani AC. Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study. Lancet Glob Heal. 2014;2(8):e460–e467. doi: 10.1016/S2214-109X(14)70256-6.
    1. Nosten F, Rogerson SJ, Beeson JG, McGready R, Mutabingwa TK, Brabin B. Malaria in pregnancy and the endemicity spectrum: What can we learn? Trends Parasitol. 2004;20(9):425–432. doi: 10.1016/j.pt.2004.06.007.
    1. Mayor A, Bardaji A, Macete E, Nhampossa T, Fonseca AM, Gonzalez R, et al. Changing trends in P. falciparum burden, immunity, and disease in pregnancy. N Engl J Med. 2015;373(17):1607–17. doi: 10.1056/NEJMoa1406459.
    1. Souza RM, Ataíde R, Dombrowski JG, Ippólito V, Aitken EH, Valle SN, et al. Placental histopathological changes associated with Plasmodium vivax infection during pregnancy. Plos Negl Trop Dis. 2013;7(2):e2071. doi: 10.1371/journal.pntd.0002071.
    1. Steketee RW, Wirima JJ, Slutsker L, Heymann DL, Breman JG. The problem of malaria and malaria control in pregnancy in sub-Saharan Africa. Am J Trop Med Hyg. 1996;55(1 Suppl):2–7. doi: 10.4269/ajtmh.1996.55.2.
    1. Menendez C. Malaria during pregnancy. Curr Mol Med. 2006;6(2):269–273. doi: 10.2174/156652406776055186.
    1. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7(2):93–104. doi: 10.1016/S1473-3099(07)70021-X.
    1. Rogerson SJ, Desai M, Mayor A, Sicuri E, Taylor SM, van Eijk AM. Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem. Lancet Infect Dis. 2018;18(4):e107-e118.
    1. Greenwood BM, Greenwood AM, Snow RW, Byass P, Bennett S, Hatib-N’Jie AB. The effects of malaria chemoprophylaxis given by traditional birth attendants on the course and outcome of pregnancy. Trans R Soc Trop Med Hyg. 1989;83(5):589–594. doi: 10.1016/0035-9203(89)90362-3.
    1. D’Alessandro U, Langerock P, Bennett S, Francis N, Cham K, Greenwood BM. The impact of a national impregnated bed net programme on the outcome of pregnancy in primigravidae in The Gambia. Trans R Soc Trop Med Hyg. 1996;90(5):487–492. doi: 10.1016/S0035-9203(96)90289-8.
    1. Menendez C, Ordi J, Ismail MR, Ventura PJ, Aponte JJ, Kahigwa E, et al. The impact of placental malaria on gestational age and birth weight. J Infect Dis. 2000;181(5):1740–1745. doi: 10.1086/315449.
    1. Boel ME, Rijken MJ, Brabin BJ, Nosten F, McGready R. The epidemiology of postpartum malaria: a systematic review. Malar J. 2012;11:114. doi: 10.1186/1475-2875-11-114.
    1. World Health Organization . A strategic framework for malaria prevention and control during pregnancy in the African Region. Brazzav: WHO Reg Off Africa; 2004. pp. 1–39.
    1. Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. JAMA. 2013;309(6):594–604. doi: 10.1001/jama.2012.216231.
    1. Coulibaly SO, Kayentao K, Taylor S, Guirou EA, Khairallah C, Guindo N, et al. Parasite clearance following treatment with sulphadoxine-pyrimethamine for intermittent preventive treatment in Burkina-Faso and Mali: 42-day in vivo follow-up study. Malar J. 2014;13:41. doi: 10.1186/1475-2875-13-41.
    1. Menendez C, Alonso P, de Barcelona U. Guidelines and considerations for testing malaria vaccines in pregnant women. Hum Vaccin. 2010;6(1):21–26. doi: 10.4161/hv.6.1.10331.
    1. WHO Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of eighth biannual meeting (September 2015) Malar J. 2016;15(1):117. doi: 10.1186/s12936-016-1169-x.
    1. Cosmic 2018. Community-based malaria screening and treatment for pregnant women receiving standard intermittent preventive treatment with sulfadoxine-pyrimethamine: a multicentre (The Gambia, Burkina Faso and Benin) cluster randomised controlled trial. Clin Infect Dis. 2018;(Xx Xxxx):1–11 Available from: .
    1. Ruizendaal E, Tahita MC, Traore-Coulibaly M, Tinto H, Schallig HDFH, Mens PF. Presence of quintuple dhfr N51, C59, S108 - dhps A437, K540 mutations in Plasmodium falciparum isolates from pregnant women and the general population in Nanoro, Burkina Faso. Mol Biochem Parasitol. 2017;217:13–15. doi: 10.1016/j.molbiopara.2017.08.003.
    1. Ruizendaal E, Tahita MC, Geskus RB, Versteeg I, Scott S, d’Alessandro U, et al. Increase in the prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates collected from early to late pregnancy in Nanoro, Burkina Faso. Malar J. 2017;16(1):179. doi: 10.1186/s12936-017-1831-y.
    1. Berry I, Walker P, Tagbor H, Bojang K, Coulibaly SO, Kayentao K, et al. Seasonal dynamics of malaria in pregnancy in West Africa: evidence for carriage of infections acquired before pregnancy until first contact with antenatal care. Am J Trop Med Hyg. 2018;98(2):534–542. doi: 10.4269/ajtmh.17-0620.
    1. Das S, Jang IK, Barney B, Peck R, Rek JC, Arinaitwe E, et al. Performance of a high-sensitivity rapid diagnostic test for plasmodium falciparum malaria in asymptomatic individuals from Uganda and Myanmar and naive human challenge infections. Am J Trop Med Hyg. 2017;97(5):1540–1550. doi: 10.4269/ajtmh.17-0245.
    1. Hofmann NE, Gruenberg M, Nate E, Ura A, Rodriguez-Rodriguez D, Salib M, et al. Assessment of ultra-sensitive malaria diagnosis versus standard molecular diagnostics for malaria elimination: an in-depth molecular community cross-sectional study. Lancet Infect Dis. 2018;18(10):1108–1116. doi: 10.1016/S1473-3099(18)30411-0.
    1. Vásquez AM, Medina AC, Tobón-Castaño A, Posada M, Vélez GJ, Campillo A, et al. Performance of a highly sensitive rapid diagnostic test (HS-RDT) for detecting malaria in peripheral and placental blood samples from pregnant women in Colombia. Plos One. 2018;13(8):e0201769. doi: 10.1371/journal.pone.0201769.
    1. Plucinski MM, Rogier E, Dimbu PR, Fortes F, Halsey ES, Aidoo M. Estimating the added utility of highly sensitive histidine-rich protein 2 detection in outpatient clinics in sub-Saharan Africa. Am J Trop Med Hyg. 2017;97(4):1159–1162. doi: 10.4269/ajtmh.17-0262.
    1. Pekyi D, Ampromfi AA, Tinto H, Traore-Coulibaly M, Tahita MC, Valea I, et al. Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med. 2016;374(10):913–927. doi: 10.1056/NEJMoa1508606.
    1. Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, et al. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N Engl J Med. 2016;374(10):928–939. doi: 10.1056/NEJMoa1509150.
    1. Millat-Martínez P, Ila R, Laman M, Robinson L, Karunajeewa H, Abel H, et al. Electrocardiographic safety of repeated monthly dihydroartemisinin-piperaquine as a candidate for mass drug administration. Antimicrob Agents Chemother. 2018;62(12):e01153-18.
    1. Millat-Martínez P, Bassat Q. Reappraising the cardiosafety of dihydroartemisinin-piperaquine. Lancet Infect Dis. 2018;18(8):824–826. doi: 10.1016/S1473-3099(18)30360-8.
    1. Ministère de la santé. Plan d’action District Sanitaire de Nanoro. Ouagadougou, Burkina Faso. 2019.
    1. Derra K, Rouamba E, Kazienga A, Ouedraogo S, Tahita MC, Sorgho H, et al. Profile: Nanoro health and demographic surveillance system. Int J Epidemiol. 2012;41(5):1293–1301. doi: 10.1093/ije/dys159.
    1. PNLP . PNLP: Directives nationales pour la prise en charge du paludisme dans les formations sanitaires du Burkina Faso. 2014.
    1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England) 2012;380(9859):2095–2128. doi: 10.1016/S0140-6736(12)61728-0.
    1. Kyabayinze DJ, Tibenderana JK, Odong GW, Rwakimari JB, Counihan H. Operational accuracy and comparative persistent antigenicity of HRP2 rapid diagnostic tests for Plasmodium falciparum malaria in a hyperendemic region of Uganda. Malar J. 2008;7:221. doi: 10.1186/1475-2875-7-221.
    1. Abacassamo F, Enosse S, Aponte JJ, Gómez-Olivé FX, Quintó L, Mabunda S, et al. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health. 2004;9(2):200–208. doi: 10.1046/j.1365-3156.2003.01182.x.
    1. Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, Espasa M, et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis. 2006;194(3):276–285. doi: 10.1086/505431.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj